Beam Therapeutics set out to show how the precision of base-editing could produce new genetic medicines addressing a wide range of diseases. That goal may yet be realized, but the company is now ...

I covered Beam Therapeutics (BEAM) in April last year, when the stock had a market cap of $3.7bn. Today, despite some derisking events, it has a market cap of $2.6bn. The stock price has fallen 30% as ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...